TY - JOUR
T1 - Prognostic impact of serum bilirubin level on long-term renal survival in IgA nephropathy
AU - Tanaka, Shigeru
AU - Ninomiya, Toshiharu
AU - Masutani, Kosuke
AU - Nagata, Masaharu
AU - Tsuchimoto, Akihiro
AU - Tsuruya, Kazuhiko
AU - Kitazono, Takanari
N1 - Funding Information:
The authors would like to express our appreciation to the investigators at the participating institutions: Tetsuhiko Yoshida, M.D., Kei Hori, M.D., Ph.D., Takashi Inenaga, M.D., Akinori Nagashima, M.D., Ph.D., Tadashi Hirano, M.D. and Hideko Noguchi. This work was supported in part by Grants-in-Aid for Scientific Research (Nos. 23590400 and 24593302) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
Publisher Copyright:
© 2015, Japanese Society of Nephrology.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background: Serum bilirubin has been recognized as a novel endogenous antioxidant. The aim of our study was to evaluate the impact of serum bilirubin on kidney prognosis in IgA nephropathy (IgAN). Methods: We followed retrospectively 694 patients with IgAN diagnosed by renal biopsy between 1982 and 2010. The risk factors for developing end-stage renal disease (ESRD) were estimated using a Cox proportional hazard model. Predictive performance between models with or without serum bilirubin was evaluated by calculating the net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: Seventy-seven patients developed ESRD during the median 4.9 years of follow-up. Estimated glomerular filtration rate, proteinuria and histological severity were inversely related to bilirubin levels. In multivariate analysis, serum bilirubin was an independent risk factor for ESRD (hazard ratio for every 0.1 mg/dL decrease in serum bilirubin, 1.18; 95 % CI, 1.04–1.33). The incidence rate of ESRD decreased linearly with the increases in bilirubin levels (P for trend <0.01). When bilirubin was incorporated into a model with conventional ESRD risk factors, the NRI and IDI were 0.281 (P = 0.02) and 0.019 (P = 0.01), respectively. Conclusions: We demonstrated that lower bilirubin levels were significantly associated with higher risk of ESRD in IgAN. In addition, bilirubin provided incremental predictive value in the risk assessment for progression of IgAN beyond that provided by standard risk factors.
AB - Background: Serum bilirubin has been recognized as a novel endogenous antioxidant. The aim of our study was to evaluate the impact of serum bilirubin on kidney prognosis in IgA nephropathy (IgAN). Methods: We followed retrospectively 694 patients with IgAN diagnosed by renal biopsy between 1982 and 2010. The risk factors for developing end-stage renal disease (ESRD) were estimated using a Cox proportional hazard model. Predictive performance between models with or without serum bilirubin was evaluated by calculating the net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: Seventy-seven patients developed ESRD during the median 4.9 years of follow-up. Estimated glomerular filtration rate, proteinuria and histological severity were inversely related to bilirubin levels. In multivariate analysis, serum bilirubin was an independent risk factor for ESRD (hazard ratio for every 0.1 mg/dL decrease in serum bilirubin, 1.18; 95 % CI, 1.04–1.33). The incidence rate of ESRD decreased linearly with the increases in bilirubin levels (P for trend <0.01). When bilirubin was incorporated into a model with conventional ESRD risk factors, the NRI and IDI were 0.281 (P = 0.02) and 0.019 (P = 0.01), respectively. Conclusions: We demonstrated that lower bilirubin levels were significantly associated with higher risk of ESRD in IgAN. In addition, bilirubin provided incremental predictive value in the risk assessment for progression of IgAN beyond that provided by standard risk factors.
UR - http://www.scopus.com/inward/record.url?scp=84951904989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951904989&partnerID=8YFLogxK
U2 - 10.1007/s10157-015-1096-0
DO - 10.1007/s10157-015-1096-0
M3 - Article
C2 - 25700934
AN - SCOPUS:84951904989
SN - 1342-1751
VL - 19
SP - 1062
EP - 1070
JO - Clinical and Experimental Nephrology
JF - Clinical and Experimental Nephrology
IS - 6
ER -